# Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis

> **NCT00985270** · PHASE4 · COMPLETED · sponsor: **University of Oulu** · enrollment: 12 (estimated)

## Conditions studied

- Glucose Tolerance

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00985270
- **Lead sponsor:** University of Oulu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2011-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985270, "Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00985270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*